Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)-Reference-Cited by-同舟云学术

Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)

Published:2007-03 Issue:1 Volume:2 Page:39-47
ISSN:1176-9114
Container-title:International Journal of Nanomedicine
language:en
Short-container-title:International Journal of Nanomedicine

Author:

Dinesen Lotte,Travis Simon

Publisher

Informa UK Limited

Subject

Organic Chemistry,Drug Discovery,General Medicine,Biomaterials,Bioengineering,Biophysics,Pharmaceutical Science

Reference54 articles.

1. Alfadhli AA, McDonald JW, Feagan BG. 2003. Methotrexate for induction of remission in refractory Crohn's disease (Cochrane Review). Cochrane Database Syst Rev, 1:CD003459.

2. Biologic Therapy for Inflammatory Bowel Disease

3. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

5. Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of inflammation in autoimmune disease: a therapeutic target;Frontiers in Immunology;2023-10-04

2. Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics;Journal of Gastrointestinal and Liver Diseases;2022-06-12

3. Applications of nanotechnology in pharmaceutical products;Applications of Nanotechnology in Drug Discovery and Delivery;2022

4. Recent Developments and Challenges in Nanoformulations Targeting Various Ailments of the Colon;Nanoformulations in Human Health;2020

5. Biologic Therapy of Crohn’s Disease: Certolizumab;Crohn's Disease and Ulcerative Colitis;2017